{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-007369","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.175941+00:00","generated_at":"2026-06-26T00:51:29.463929+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cyclerion reports Q1 net loss $13.0M; CY6463 MELAS data expected Q2 2022","bullets":["Net loss of $13.0M in Q1 2022 vs $13.4M in Q1 2021; cash balance $41M (down from $54M).","R&D expenses rose to $9.7M from $8.0M due to external research costs; G&A fell to $4.0M from $5.4M.","MELAS study enrollment closed; topline data expected Q2 2022.","CIAS study enrollment closed; topline data expected Q3 2022.","Alzheimer's disease with vascular pathology (ADv) study enrollment ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-007369","json":"https://secwatch.observer/filing/0000950170-22-007369.json","markdown":"https://secwatch.observer/filing/0000950170-22-007369.md","text":"https://secwatch.observer/filing/0000950170-22-007369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022007369/0000950170-22-007369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022007369/cycn-20220504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:51:29.463929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}